Vertex Pharmaceuticals Incorporated’s VRTX third-quarter 2025 results were strong as it beat estimates for both earnings and ...

And I do have several favorite stocks that fit that description. My top growth stock to buy in November is one that I've ...

Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.80 per share for the third quarter of 2025, surpassing the Zacks ...

Vertex Pharmaceuticals VRTX reported strong second-quarter results driven by the continued robust uptake of its cystic fibrosis triple-combination therapy, Trikafta/Kaftrio. Product revenue of $2.49 ...

Strong Trikafta/Kaftrio demand, along with contributions from Alyftrek, Casgevy and Journavx, may have helped VRTX outperform ...

Vertex VRTX reported third-quarter results highlighted by strong uptake of its cystic fibrosis triple combination therapy, Trikafta/Kaftrio, in the United States and internationally. Quarterly product ...

-More than 1,200 children are newly eligible for a medicine that could treat the underlying cause of their disease- About Cystic Fibrosis Cystic fibrosis (CF) is a rare, life-shortening genetic ...

BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that data on TRIKAFTA ® (elexacaftor/tezacaftor/ivacaftor and ivacaftor ...

Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals ...

Vertex Pharmaceuticals Incorporated VRTX is scheduled to release fourth-quarter and full-year 2023 results on Feb 5, after market close. The company has an impressive earnings surprise history, ...